EUVIMEDEUVIMED entdecken
Open Access

VEGF Secretion Drives Bone Formation in Classical MAP2K1+ Melorheostosis

Jules D Allbritton-King iD, Jyotirindra Maity, Amit Patel iD, Robert A Colbert iD, Fatemeh Navid iD, Timothy Bhattacharyya iD

Journal of Bone and Mineral Research · 01.12.2023 · 38 (12) · 1834-1845

DOI: 10.1002/jbmr.4915 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Bone and Mineral Research, online erschienen am 01.12.2023. Verfasst von Jules D Allbritton-King und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Investigative Orthopedics Surgery Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of He…. Hauptthemen laut MEDLINE: Melorheostosis, Osteogenesis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, Intramural NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with classical melorheostosis exhibit exuberant bone overgrowth in the appendicular skeleton, resulting in pain and deformity with no known treatment. Most patients have somatic, mosaic mutations in MAP2K1 (encoding the MEK1 protein) in osteoblasts and overlying skin. As with most rare bone diseases, lack of affected tissue has limited the opportunity to understand how the mutation results in excess bone formation. The aim of this study was to create a cellular model to study melorheostosis. We obtained patient skin cells bearing the MAP2K1 mutation (affected cells), and along with isogenic control normal fibroblasts reprogrammed them using the Sendai virus method into induced pluripotent stem cells (iPSCs). Pluripotency was validated by marker staining and embryoid body formation. iPSCs were then differentiated to mesenchymal stem cells (iMSCs) and validated by flow cytometry. We confirmed retention of the MAP2K1 mutation in iMSCs with polymerase chain reaction (PCR) and confirmed elevated MEK1 activity by immunofluorescence staining. Mutation-bearing iMSCs showed significantly elevated vascular endothelial growth factor (VEGF) secretion, proliferation and collagen I and IV secretion. iMSCs were then differentiated into osteoblasts, which showed increased mineralization at 21 days and increased VEGF secretion at 14 and 21 days of differentiation. Administration of VEGF to unaffected iMSCs during osteogenic differentiation was sufficient to increase mineralization. Blockade of VEGF by bevacizumab reduced mineralization in iMSC-derived affected osteoblasts and in affected primary patient-derived osteoblasts. These data indicate that patient-derived induced pluripotent stem cells recreate the elevated MEK1 activity, increased mineralization, and increased proliferation seen in melorheostosis patients. The increased bone formation is driven, in part, by abundant VEGF secretion. Modifying the activity of VEGF (a known stimulator of osteoblastogenesis) represents a promising treatment pathway to explore. iPSCs may have wide applications to other rare bone diseases. © 2023 American Society for Bone and Mineral Research (ASBMR).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelorheostosisOsteogenesisHumansBone and BonesCell DifferentiationMAP Kinase Kinase 1Vascular Endothelial Growth Factor A

Stichwörter der Autor:innen

MELORHEOSTOSISMINERALIZATIONOSTEOBLASTSVEGFiPSCs

Substanzen

MAP Kinase Kinase 1MAP2K1 protein, humanVascular Endothelial Growth Factor AVEGFA protein, human

Autor:innen und Institutionen

  • Clinical and Investigative Orthopedics Surgery Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.

ORCID-Profile: Jules D Allbritton-King, Amit Patel, Robert A Colbert, Fatemeh Navid, Timothy Bhattacharyya

Förderung

  • NIGMS NIH HHS
  • Intramural NIH HHS
  • NIAMS NIH HHS
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Allbritton-King, J. D., Maity, J., Patel, A., Colbert, R. A., Navid, F., & Bhattacharyya, T. (2023). VEGF Secretion Drives Bone Formation in Classical MAP2K1+ Melorheostosis. Journal of Bone and Mineral Research, 38(12), 1834-1845. https://doi.org/10.1002/jbmr.4915

Vancouver

Allbritton-King JD, Maity J, Patel A, Colbert RA, Navid F, Bhattacharyya T. VEGF Secretion Drives Bone Formation in Classical MAP2K1+ Melorheostosis. Journal of Bone and Mineral Research. 2023;38(12):1834-1845. doi:10.1002/jbmr.4915

BibTeX
@article{AllbrittonKing2023,
  author = {Allbritton-King, Jules D and Maity, Jyotirindra and Patel, Amit and Colbert, Robert A and Navid, Fatemeh and Bhattacharyya, Timothy},
  title = {VEGF Secretion Drives Bone Formation in Classical MAP2K1+ Melorheostosis},
  journal = {Journal of Bone and Mineral Research},
  year = {2023},
  volume = {38},
  number = {12},
  pages = {1834--1845},
  doi = {10.1002/jbmr.4915}
}
Kostenlos starten →